Last reviewed · How we verify
PEX010-Assisted Therapy
At a glance
| Generic name | PEX010-Assisted Therapy |
|---|---|
| Also known as | PEX010 |
| Sponsor | Filament Health Corp. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD (PHASE1)
- Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study (PHASE2)
- Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy (PHASE2)
- Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (PHASE2)
- Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy (PHASE1)
- Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication (PHASE2)
- PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study (PHASE2)
- PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |